2020
Consolidation Therapy in Primary Central Nervous System Lymphoma
Kim P, Omuro A. Consolidation Therapy in Primary Central Nervous System Lymphoma. Current Treatment Options In Oncology 2020, 21: 74. PMID: 32725379, DOI: 10.1007/s11864-020-00758-4.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyCentral nervous system lymphomaLong-term remissionNervous system lymphomaConsolidation therapyInduction therapyPerformance statusTransplant candidatesSystem lymphomaOpinion statementPrimary central nervous system lymphomaPrimary central nervous system lymphomaAutologous stem cell transplantTransplant-related mortality riskAdequate organ functionFavorable performance statusInitial induction therapyECOG performance statusHigh-dose cytarabineHigh-dose methotrexateHigh-dose chemotherapyStem cell transplantEnd of inductionHigh response rateCurative intentMyeloablative regimen
2018
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma
Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood 2018, 132: 2240-2248. PMID: 30262659, PMCID: PMC6265643, DOI: 10.1182/blood-2018-02-835496.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaOverall response ratePrimary vitreoretinal lymphomaProgression-free survivalRefractory primary central nervous system lymphomaComplete responsePartial responseVitreoretinal lymphomaGrade 3/4 hematologic toxicitiesGrade 3/4 nonhematologic toxicitiesMedian progression-free survivalCentral nervous system lymphomaDose escalation schedulePhase 1 studyNervous system lymphomaCombination of pomalidomideSignificant therapeutic activityMTD cohortNonhematologic toxicityHematologic toxicityRespiratory failureSystem lymphomaMTD determinationPrimary CNSSafety profile
2017
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery 2017, 7: 1018-1029. PMID: 28619981, PMCID: PMC5581705, DOI: 10.1158/2159-8290.cd-17-0613.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAdultAgammaglobulinaemia Tyrosine KinaseAgedAged, 80 and overAntineoplastic AgentsCARD Signaling Adaptor ProteinsCentral Nervous System NeoplasmsDrug Resistance, NeoplasmFemaleGuanylate CyclaseHumansLymphoma, B-CellMaleMaximum Tolerated DoseMiddle AgedMutationPiperidinesProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazolesPyrimidinesTreatment OutcomeYoung AdultConceptsPrimary central nervous system lymphomaBruton's tyrosine kinaseB-cell lymphomaRefractory B-cell lymphomaB cell antigen receptorCentral nervous system lymphomaRole of BTKDiffuse large B-cell lymphomaLarge B-cell lymphomaPhase I clinical trialClass BTK inhibitorIncomplete tumor responseNervous system lymphomaToll-like receptorsPI3K/mTORIbrutinib responseCNS lymphomaClinical responseComplete responseReceptor-associated proteinSystem lymphomaActivation markersTumor responseClinical trialsPCNSL cells
2016
Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma
Grommes C, Pastore A, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L. Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma. Blood 2016, 128: 783. DOI: 10.1182/blood.v128.22.783.783.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaProgression-free survivalSecondary CNS lymphomaMedian progression-free survivalHigh-dose methotrexate chemotherapyCentral nervous system lymphomaNervous system lymphomaAdverse eventsCNS lymphomaCombination armClinical responseMethotrexate chemotherapySystem lymphomaGrade 4 adverse eventsRecurrent/refractory diseaseAggressive primary brain tumorCerebrospinal fluid involvementCNS lymphoma patientsManageable adverse eventsGrade 3 toxicityMethotrexate-based chemotherapyEnd-organ functionNormal end-organ functionUrinary tract infectionPrimary brain tumorsA Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning
Scordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, Dahi PB, Moskowitz CH, Giralt SA, Sauter CS. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Transplantation And Cellular Therapy 2016, 23: 38-43. PMID: 27713090, PMCID: PMC5518313, DOI: 10.1016/j.bbmt.2016.09.024.Peer-Reviewed Original ResearchConceptsAutologous stem cell transplantationPrimary central nervous system lymphomaSecondary central nervous system lymphomaCentral nervous system lymphomaProgression-free survivalNervous system lymphomaTransplantation-related mortalityStem cell transplantationOverall survivalSystem lymphomaCyclophosphamide conditioningNonhematologic toxicityCell transplantationTreatment strategiesTime of ASCTFavorable progression-free survivalHigh-dose therapyBusulfan areaBusulfan dosingAdult patientsPatient characteristicsMedian numberToxicity burdenPatientsConsiderable toxicityLong-term survival in AIDS-related primary central nervous system lymphoma
Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro-Oncology 2016, 19: 99-108. PMID: 27576871, PMCID: PMC5193026, DOI: 10.1093/neuonc/now155.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyWhole brain radiotherapyPrimary central nervous system lymphomaCentral nervous system lymphomaAR-PCNSLNervous system lymphomaHD-MTXLong-term survivalMulticenter analysisSystem lymphomaAdvent of cARTLong-term disease-free survivalLonger progression-free survivalSan Francisco General HospitalHigh-dose methotrexateDisease-free survivalProgression-free survivalOptimal therapeutic approachTherapy-related factorsFirst-line interventionPost-cART eraLong-term toxicityAntiretroviral therapyBrain radiotherapyFavorable survival
2015
Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial.
Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquieres H, Houot R, Delwail V, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Tanguy M, Omuro A, Hoang-Xuan K. Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial. Journal Of Clinical Oncology 2015, 33: 2035-2035. DOI: 10.1200/jco.2015.33.15_suppl.2035.Peer-Reviewed Original Research
2014
Methotrexate re-challenge for recurrent primary central nervous system lymphoma
Pentsova E, DeAngelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. Journal Of Neuro-Oncology 2014, 117: 161-165. PMID: 24481997, PMCID: PMC5256683, DOI: 10.1007/s11060-014-1370-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCentral Nervous System NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMethotrexateMiddle AgedNeoplasm Recurrence, LocalPrognosisRetreatmentRetrospective StudiesSalvage TherapyTreatment OutcomeConceptsPrimary CNS lymphomaKarnofsky performance scoreProgression-free survivalInitial diagnosisRecurrent primary central nervous system lymphomaPrimary central nervous system lymphomaMedian Karnofsky performance scoreMedian progression-free survivalCentral nervous system lymphomaObjective response rateNervous system lymphomaMedian OSCNS lymphomaFree survivalRecurrent diseaseSalvage treatmentFirst relapsePartial responsePCNSL patientsPrognostic factorsComplete responseMedian ageSystem lymphomaDisease relapseMedian time
2012
First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-Analysis
Kasenda B, Ferreri A, Maturano E, Bromberg J, Ghesquieres H, Ferlay C, Blay J, Xuan K, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill B, Bairey O, Gloy V, Bhatnagar N, Haug S, Rahner S, Illerhaus G, Briel M. First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-Analysis. Blood 2012, 120: 3655. DOI: 10.1182/blood.v120.21.3655.3655.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaIndividual patient dataCentral nervous system lymphomaElderly PCNSL patientsMedian age 68Improved overall survivalFirst-line treatmentNervous system lymphomaOverall survivalElderly patientsPCNSL patientsSystematic reviewEligible studiesPerformance statusSystem lymphomaFunctional statusAge 68Patient dataBetter outcomesIndividual Patient Data Meta-AnalysisDifferent first-line treatmentsMultivariable Cox regression modelsFollowing baseline characteristicsImmunocompetent PCNSL patientsCo-morbidity indexMulticenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma
Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A, Consortium F. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leukemia & Lymphoma 2012, 54: 58-61. PMID: 22656234, PMCID: PMC4802006, DOI: 10.3109/10428194.2012.698736.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaRecurrent primary central nervous system lymphomaCentral nervous system lymphomaNervous system lymphomaSystem lymphomaDay 1Prospective multicenter phase II trialMedian progression-free survivalMulticenter phase II studyMulticenter phase II trialAggressive salvage treatmentMedian overall survivalPhase II studyPhase II trialProgression-free survivalCycles of consolidationEvaluable patientsII trialSalvage treatmentII studyImmunocompetent patientsOverall survivalComplete responseRetrospective studyPatientsPrimary Central Nervous System Lymphomas
Graber J, Omuro A. Primary Central Nervous System Lymphomas. 2012, 125-133. DOI: 10.1002/9781118321478.ch12.Peer-Reviewed Original ResearchPrimary CNS lymphomaHigh-dose methotrexate-based chemotherapyPrimary central nervous system lymphomaCentral nervous system lymphomaMethotrexate-based chemotherapyNervous system lymphomaNon-Hodgkin lymphomaLong-term survivalCNS lymphomaOptimal regimenImmunosuppressed patientsSystem lymphomaAppropriate therapyDisease relapseEarly suspicionDiagnostic accuracyLymphomaInappropriate interventionsPatientsImmunocompetentRegimenChemotherapyRelapseRadiotherapyNeurotoxicity
2011
Primary central nervous system lymphoma
Graber JJ, Omuro A. Primary central nervous system lymphoma. Current Opinion In Neurology 2011, 24: 633-640. PMID: 21968551, DOI: 10.1097/wco.0b013e32834cbdef.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaReduced-dose radiotherapyProgression-free survivalNervous system lymphomaNeurotoxicity ratesSystem lymphomaChemotherapy-only treatmentHigh-dose methotrexateStem cell rescueWhole brain radiotherapyHigh-dose chemotherapyPhase II studyWorse cognitive outcomesChemotherapy regimenSalvage treatmentII studyOlder patientsOverall survivalBrain damageChemotherapyRadiotherapyAdditional neurotoxicityRoutine practiceNeuropsychological evaluationProphylactic intrathecal chemotherapy in primary CNS lymphoma
Sierra del Rio M, Ricard D, Houillier C, Navarro S, Gonzalez-Aguilar A, Idbaih A, Kaloshi G, Elhallani S, Omuro A, Choquet S, Soussain C, Hoang-Xuan K. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. Journal Of Neuro-Oncology 2011, 106: 143-146. PMID: 21739169, DOI: 10.1007/s11060-011-0649-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHumansInjections, SpinalKarnofsky Performance StatusLomustineLymphomaMaleMethotrexateMethylprednisoloneMiddle AgedNeoplasm Recurrence, LocalNeuroprotective AgentsProcarbazineRetrospective StudiesYoung AdultConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaNervous system lymphomaProphylactic intrathecal chemotherapyIntrathecal chemotherapySystem lymphomaIntrathecal prophylaxisHigh-dose intravenous methotrexateRetrospective single-center studyObjective response ratePatterns of relapsePrimary CNS lymphomaProgression-free survivalSingle-center studyHigh intravenous dosesIntrathecal chemoprophylaxisIntravenous methotrexateProphylaxis withdrawalChemotherapy regimenCNS lymphomaSystemic chemotherapyKarnofsky indexOverall survivalIntravenous dosesMedian ageMethotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy
Morris PG, Abrey LE, Reiner AS, Wu N, Panageas KS, Seko BS, Deangelis LM, Omuro A. Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leukemia & Lymphoma 2011, 52: 1891-1897. PMID: 21699456, DOI: 10.3109/10428194.2011.585527.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveCentral Nervous System NeoplasmsCombined Modality TherapyCytarabineFemaleHumansKarnofsky Performance StatusMaleMethotrexateMiddle AgedProcarbazinePrognosisRituximabSurvival AnalysisVincristineConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaProgression-free survivalNervous system lymphomaMTX AUCMethotrexate areaSystem lymphomaMedian Karnofsky performance status (KPS) scoreIntra-patient dose escalationProspective phase II trialKarnofsky performance status scoreLow-dose radiotherapyFirst chemotherapy cyclePerformance status scorePhase II trialImproved tumor controlSubstantial inter-individual variabilityChemotherapy cyclesII trialMTX exposureOverall survivalDose escalationMedian agePrognostic factorsInter-individual variability
2010
Methotrexate (M) area under the curve (AUC) and creatinine clearance (CrCl) as prognostic factors in primary central nervous system lymphoma (PCNSL).
Morris P, Abrey L, Reiner A, Panageas K, Seko B, DeAngelis L, Omuro A. Methotrexate (M) area under the curve (AUC) and creatinine clearance (CrCl) as prognostic factors in primary central nervous system lymphoma (PCNSL). Journal Of Clinical Oncology 2010, 28: 2040-2040. DOI: 10.1200/jco.2010.28.15_suppl.2040.Peer-Reviewed Original Research
2007
Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly
Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. Journal Of Neuro-Oncology 2007, 85: 207-211. PMID: 17896079, DOI: 10.1007/s11060-007-9397-0.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaIntra-thecal chemotherapyFavorable toxicity profileComplete responseToxicity profilePrimary central nervous system lymphomaMedian event-free survivalCentral nervous system lymphomaMedian overall survivalEvent-free survivalNervous system lymphomaNew alternative treatmentLow response rateInduction chemotherapyInnovative regimenCNS lymphomaElderly patientsIntestinal obstructionOverall survivalPCNSL patientsYounger patientsSystem lymphomaConsecutive seriesEfficacy resultsGrade 3Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report
Grimm S, Pulido J, Jahnke K, Schiff D, Hall A, Shenkier T, Siegal T, Doolittle N, Batchelor T, Herrlinger U, Neuwelt E, Laperriere N, Chamberlain M, Blay J, Ferreri A, Omuro A, Thiel E, Abrey L. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Annals Of Oncology 2007, 18: 1851-1855. PMID: 17804469, DOI: 10.1093/annonc/mdm340.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCombined Modality TherapyConsensusEye NeoplasmsFemaleHIV SeronegativityHumansLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsPrimary intraocular lymphomaOverall survivalMedian timeFocal therapyPrimary central nervous system lymphomaMedian ECOG performance statusCentral nervous system lymphomaTreatment typeECOG performance statusPositive CSF cytologyNervous system lymphomaBrain relapseMedian PFSMedian progressionPIOL patientsUncommon subsetIntraocular lymphomaPerformance statusRelapse patternsRetinal biopsyTreatment toxicityMedian ageSystem lymphomaInitial treatmentCSF cytology
2006
Chemotherapy for primary central nervous system lymphoma.
Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma. Neurosurgical FOCUS 2006, 21: e12. PMID: 17134114, DOI: 10.3171/foc.2006.21.5.13.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaHigh-dose methotrexateUse of chemotherapyNervous system lymphomaElderly patientsSystem lymphomaSuch elderly patientsMainstay of treatmentToxic regimensChemotherapy regimensCorticosteroid agentsYounger patientsPatient ageRelapse rateRandomized trialsDifferent regimensOptimal treatmentRecent trialsTreatment paradigmHigh riskChemotherapyEffective drugsSingle agentRegimens
2005
Delayed Neurotoxicity in Primary Central Nervous System Lymphoma
Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, DeAngelis LM, Abrey LE. Delayed Neurotoxicity in Primary Central Nervous System Lymphoma. JAMA Neurology 2005, 62: 1595-1600. PMID: 16216945, DOI: 10.1001/archneur.62.10.1595.Peer-Reviewed Original ResearchConceptsPrimary central nervous lymphomaPathophysiologic mechanismsPrimary central nervous system lymphomaMemorial Sloan-Kettering Cancer CenterTreatment-related toxic effectsCentral nervous system lymphomaDiffuse white matter diseaseAvailable autopsy dataProgressive subcortical dementiaMental status changesNervous system lymphomaDepartment of NeurologyWhite matter damagePotential risk factorsWhite matter diseaseFrontal-subcortical circuitsMicrovascular alterationsNeurologic deteriorationCumulative incidenceClinical courseImproved survivalRetrospective reviewSystem lymphomaClinical findingsSubcortical dementia